Impact of Carbapenem Peri-Transplant Prophylaxis and Risk of Extended-Spectrum Cephalosporin-Resistant Enterobacterales Early Urinary Tract Infection in Kidney Transplant Recipients: A Propensity Score-Matched Analysis

Suwadee Aramwittayanuks1, Kumthorn Malatham2, Surasak Kantachuvesir3,4, Nattapon Arpornsujaritkun4,5, Patumsri Chootip6 and Jackrapong Bruminhent2,4,6*

1 Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 2 Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 3 Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 4 Ramathibodi Excellence Center for Organ Transplantation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 5 Vascular and Transplant Unit, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 6 Department of Nursing Services, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Background: Urinary tract infection (UTI) is the most common bacterial infection after kidney transplantation (KT), leading to unfavorable clinical and allograft outcomes. Gram-negative uropathogenic bacteria are frequently encountered especially extended-spectrum cephalosporin-resistant (ESC-R) Enterobacterales (EB), causing UTI early after KT.

Methods: A retrospective single transplant study was conducted between January 2016 and December 2019. We performed 1:1 nearest-neighbor propensity score matching without replacement using recipient age, recipient sex, induction, transplant year, human leukocyte antigen, cold ischemia time, and panel-reactive antibody before analyses. Cumulative incidence of ESC-R EB early (within 14 days after KT) UTI was estimated by the Kaplan–Meier method. Risk factors for ESC-R EB early UTI were analyzed by a Cox proportional hazards model. Variables measured after transplantation were considered time-dependent covariates.

Results: We included 620 KT recipients (37% women; mean age ± SD, 43 ± 11 years). Overall, 64% and 76% received deceased-donor allograft and induction therapy. Sixty-five (10%) and 555 (90%) received carbapenems and cefuroxime peri-transplant prophylaxis, respectively. Early UTI occurred in 183 (30%) patients, 52% caused by ESC-R EB. Propensity score matching produced 65 well-balanced pairs. During a 14-day follow-up, the cumulative incidence of ESC-R EB early UTI was 5 and 28% in
the carbapenems and cefuroxime groups, respectively (log-rank test = 0.003). Peri-transplant carbapenems prophylaxis was a protective factor against ESC-R EB after KT (hazard ratio, 0.19; 95% confidence interval, 0.05–0.64; p = 0.008). Clinical and allograft outcomes did not differ significantly between the groups.

Conclusions: In the setting where ESC-R EB UTI is common among KT recipients, carbapenems peri-transplant prophylaxis could protect against the occurrence of early ESC-R EB UTI after KT. Further prospective studies should focus on this specific infection prevention strategy.

Keywords: antibiotic prophylaxis, kidney transplantation, propensity score-matched analysis, extended-spectrum beta-lactamase, pyelonephritis

INTRODUCTION

Chronic kidney disease is a significant national public health problem in patients reaching end-stage renal failure. One of the most effective treatments is kidney transplantation (KT) (1). Despite noticeable progress in surgical procedures and immunosuppression after KT, urinary tract infection (UTI) remains an important problem in KT recipients (2–5). UTI is the most frequent infectious complication after KT, occurring in up to 86% of cases (6). Therefore, prevention of UTI must be considered for successful transplantation (7, 8).

The etiological pathogens in UTIs vary depending on environments, hosts’ immune status, anatomical structure, virulence factors, or drug susceptibilities. In KT recipients, an emerging multi-drug resistant pathogen, especially Enterobacterales (EB), has been emerging and challenging in clinical practice (9). Uropathogenic Escherichia coli (UPEC) is a common bacterial pathogen causing UTIs in KT recipients. Several virulence factors have offered an opportunity to infect vulnerable hosts, mainly, Chaperone-Usher fibers (10, 11). Furthermore, fimbriae have been reported to affect biofilm growth, especially during the early course after KT since KT recipients are indwelled with a urinary catheter and ureteral stent placement (12, 13).

Extended-spectrum cephalosporin-resistant (ESC-R) EB such as E. coli and Klebsiella pneumoniae were pathogenic for UTI, causing high incidences of infection in KT patients in our setting and internationally (8, 14). Even when antibiotics are used peri-operatively, this pathogen can still survive because it has many mechanisms for antibiotic resistance. However, selecting an appropriate antibiotic is believed to decrease the chance of UTI from this particular bacterium (15). Cefuroxime has been utilized as routine perioperative prophylaxis for KT recipients at our center, although some clinicians sometimes switch to carbapenems due to a concern of an emerging ESC-R EB early UTI after the transplant late at our institution. In the meantime, using broader spectrum antibiotics could place patients at risk of acquiring multi-drug resistant pathogens is concerning. Therefore, in the present study, we aimed to determine the impact of carbapenems given perioperatively on the incidence of ESC-R EB early UTI among KT recipients whether carbapenems proposed as an appropriate antibiotic that provide an adequate coverage could decrease the rate of ESC-R EB UTI in these vulnerable population.

MATERIALS AND METHODS

Population Study
We included all patients aged ≥18 years who were scheduled to undergo KT at Ramathibodi Hospital between January 2016 and December 2019. The patients were administered intravenous cefuroxime 1.5 g every 8 h or intravenous carbapenems with peri-transplant (first 24 h) prophylaxis started at 30 min before the incision. Patients who received antibiotics other than cefuroxime and carbapenems were excluded from the study. The primary objective was to investigate the effectiveness of carbapenems as prophylactic antibiotics in KT surgery compared with a routine antibiotic (cefuroxime) in preventing ESC-R EB early UTI in KT recipients. The secondary objective was to assess the clinical characteristics, other risk factors, and ESC-R EB early UTI outcomes in KT recipients.

UTI Definitions
UTI was defined in accordance with the guidelines from the American Society of Transplantation Infectious Diseases Community of Practice 2019 (Supplementary Table S1) (16). Early UTI was defined as UTI that occurred within 14 days after KT. All KT recipients were preemptively screened for UTI after surgery. Patients with asymptomatic bacteriuria were considered to have a UTI in this study because there is no definite recommendation for treatment of these patients and most responsible teams would provide an antibiotic for this condition during the perioperative period. Urine analysis and culture were performed on days 3, 5, 7, 10, and 14 after KT. Only early UTIs caused by E. coli and K. pneumoniae were evaluated for ESC-R EB. These organisms (including E. coli and K. pneumoniae) demonstrated resistance to ESC such as ceftriaxone or cefotaxime with a minimum inhibitory concentration (MIC) > 1 mg/L according to the criteria of the Clinical and Laboratory Standards Institute (17). The Sensititre system (Thermo Fisher Scientific, Oakwood Village, OH) was used as an in vitro diagnostic product by the clinical and laboratory standard institute broth microdilution method for clinical susceptibility testing of EB.
The cefuroxime group comprised KT recipients who received cefuroxime for perioperative prophylaxis, while the carbapenem group comprised KT recipients who received meropenem, imipenem, or ertapenem for perioperative prophylaxis.

Data Collection
The following data were collected: demographic data, comprising sex, age, and etiology of end-stage renal disease; transplant factors, comprising year of transplant, type of allograft, type of immunosuppressants, human leukocyte antigen (HLA) mismatch number, percentage of panel reactive antibody (PRA), donor age and sex, and operation time; UTI data, comprising observed symptoms, type of UTI, pathogens, peri-transplant antibiotic prophylaxis, durations of urinary catheterization and stent after surgery, history of fever in donor, date of diagnosis, and date of initiation and discontinuation of treatment; and outcome data, comprising date of treatment termination, complications such as peri-allograft collection, bacteremia, total length of hospital stay, overall and UTI-related mortality, and allograft function.

Analyses
Data analyses were carried out using Stata version 12.0 software (StataCorp, College Station, TX) in both whole cohort and propensity score-matched cohort. One-to-one nearest-neighbor propensity score matching using recipient age, recipient sex, induction, transplant year, HLA match, PRA antibody, and cold ischemic time (CIT) without replacement was performed before analyses. The demographic analysis was based on reports of ESC-R EB UTI in patients in a descriptive analysis, and the demographic data were reported as percentage or median. Cumulative incidence of ESC-R EB UTI after KT was estimated by the Kaplan–Meier method. Risk factors for ESC-R EB UTI were analyzed by a Cox proportional hazards model. Variables measured after transplantation were considered time-dependent covariates. $P$-values < 0.05 were considered statistically significant. The study protocol was reviewed and approved by the Institutional Review Board of the Faculty of Medicine at Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (Approval number: ID MURA 2019/806).

RESULTS
Baseline Characteristics
A total of 691 KT recipients were identified during the study period (Figure 1), 620 eligible participants were included. Of those, 37 and 63% were women and men with a mean age ± SD of 43 ± 11 years. Overall, 64 and 76% received deceased-donor allograft and induction therapy. Sixty-five (10%) and 555 (90%) patients received carbapenem and cefuroxime peri-transplant prophylaxis, respectively.

After propensity score matching, there were 65 matched pairs between the two antibiotic prophylaxis groups. The baseline characteristics of the matched groups were well-balanced when evaluating standardized biases. Comparisons of the baseline characteristics between the cefuroxime and carbapenem prophylaxis groups before and after propensity score matching are shown in Table 1. The mean recipient age ± SD was 43 ± 11 years, 44% were women, and 56% were men. Most cases of end-stage renal disease occurred for unknown reasons, diabetic nephropathy, or IgA nephropathy. The baseline characteristics after propensity score matching did not differ significantly except for type of KT, because none of the living-related KT recipients received carbapenems for peri-operation prophylaxis.

![Flow chart of the present study.](figure1.png)

691 KT patients during study period

| Excluded |
|-----------------------------------------------|
| Aged <18 years (n=13) |
| Lack of documentation (n=6) |
| Loss follow-up (n=2) |
| Clindamycin prophylaxis (n=23) |
| Ciprofloxacin prophylaxis (n=3) |
| Ceftazidime prophylaxis (n=2) |
| Piperacillin/tazobactam prophylaxis (n=9) |
| Ceftriaxone prophylaxis (n=13) |

620 patients met eligibility criteria

Cefuroxime prophylaxis

- (n=555)

- *Propensity Score-Matched

Cefuroxime prophylaxis

- (n=65)

Carbapenems prophylaxis

- (n=65)
| Characteristic                              | Whole cohort | Propensity score-matched cohort* |
|--------------------------------------------|--------------|----------------------------------|
|                                            | Cefuroxime Group (n = 555) | Carbapenem group (n = 65) | p-value | Cefuroxime group (n = 65) | Carbapenem group (n = 65) | p-value |
| Recipient age (years), mean (SD)           | 43 (12)      | 41 (11)                          | 0.345    | 43 (12)      | 41 (11)                          | 0.592    |
| Recipient sex                              |              |                                  | 0.091    |              |                                  | 0.596    |
| Female                                     | 197 (36)     | 30 (46)                          |          | 27 (42)     | 30 (46)                          |          |
| Male                                       | 358 (64)     | 35 (54)                          |          | 38 (58)     | 35 (54)                          |          |
| Induction therapy, n (%)                   | 409 (74)     | 62 (95)                          | <0.001   | 62 (95)     | 62 (95)                          | >0.999   |
| Year of KT, n (%)                          |              |                                  |          |              |                                  | 0.812    |
| 2016                                       | 145 (26)     | 10 (15)                          |          | 14 (22)     | 10 (15)                          |          |
| 2017                                       | 137 (25)     | 33 (51)                          |          | 32 (49)     | 33 (51)                          |          |
| 2018                                       | 138 (25)     | 18 (28)                          |          | 15 (23)     | 18 (28)                          |          |
| 2019                                       | 135 (24)     | 4 (6)                            |          | 4 (6)       | 4 (6)                            |          |
| HLA mismatch groups, n (%)                 |              |                                  | <0.001   |              |                                  | 0.758    |
| 0, 1                                       | 148 (27)     | 2 (3)                            |          | 3 (5)       | 2 (3)                            |          |
| 2, 3                                       | 341 (61)     | 60 (92)                          |          | 61 (94)     | 60 (92)                          |          |
| 4, 5, 6                                    | 66 (12)      | 3 (5)                            |          | 1 (2)       | 3 (5)                            |          |
| CIT (h), median (IQR)                      | 14 (0.5, 18) | 17 (15, 21)                      | <0.001   | 18 (15, 21) | 17 (15, 21)                      | 0.730    |
| PRA (%), n (%)                             |              |                                  | 0.555    |              |                                  | 1.000    |
| ≤50                                        | 528 (95)     | 61 (94)                          |          | 60 (92)     | 61 (94)                          |          |
| >50                                        | 27 (5)       | 4 (6.2)                          |          | 5 (8)       | 4 (6)                            |          |
| ESKD cause, n (%)                          |              |                                  | 0.413    |              |                                  | 0.345    |
| Unknown                                    | 366 (66)     | 38 (58)                          |          | 36 (55)     | 38 (58)                          |          |
| DN                                         | 49 (9)       | 4 (6)                            |          | 9 (14)      | 4 (6)                            |          |
| MN                                         | 1 (0.2)      | 0 (0)                            |          | 0 (0)       | 0 (0)                            |          |
| IgA nephropathy                            | 37 (7)       | 11 (17)                          |          | 3 (5)       | 11 (17)                          |          |
| IgM nephropathy                            | 1 (0.2)      | 0 (0)                            |          | 0 (0)       | 0 (0)                            |          |
| MPGN                                       | 1 (0.2)      | 0 (0)                            |          | 0 (0)       | 0 (0)                            |          |
| CGN                                        | 28 (5)       | 1 (1.5)                          |          | 2 (3)       | 1 (1.5)                          |          |
| FSFGG                                      | 11 (2)       | 1 (1.5)                          |          | 3 (5)       | 1 (1.5)                          |          |
| LN                                         | 19 (3)       | 4 (6)                            |          | 5 (8)       | 4 (6)                            |          |
| HTN                                        | 15 (3)       | 3 (5)                            |          | 4 (6)       | 3 (5)                            |          |
| Others                                     | 30 (5.4)     | 3 (5)                            |          | 3 (5)       | 3 (5)                            |          |
| Donor age (years), mean (SD)               | 39 (13)      | 38 (15)                          | 0.459    | 40 (13)     | 38 (15)                          | 0.472    |
| Donor female sex, n (%)                    | 210 (39)     | 18 (28)                          | 0.127    | 17 (26)     | 18 (28)                          | 0.801    |
| Type of KT, n (%)                          |              |                                  | <0.001   |              |                                  | <0.001   |
| LRKT                                       | 222 (40)     | 0 (0)                            |          | 10 (15)     | 0 (0)                            |          |
| DDKT                                       | 333 (60)     | 65 (100)                         |          | 55 (85)     | 65 (100)                         |          |
| Operation time (min), mean (SD)            | 280 (74)     | 292 (76)                         | 0.224    | 280 (60)    | 292 (76)                         | 0.301    |
| Duration of urinary catheter (days), median (IQR) | 6 (5–7) | 6 (5–7)                          | 0.971    | 6 (5–7)     | 6 (5–7)                          | 0.805    |
| Duration of stent (days), median (IQR)     | 15 (14–16)   | 15 (14–16)                       | 0.525    | 15 (14–16)  | 15 (14–16)                       | 0.698    |
| ESC-R EB UTI, n (%)                        | 94 (17)      | 3 (5)                            | 0.01     | 18 (28)     | 3 (5)                            | <0.001   |
| Non-ESC-R EB, n (%)                        | 460 (83)     | 62 (95)                          |          | 47 (72)     | 62 (95)                          |          |
| Non-ESC-R EB UTI                           | 74 (13)      | 11 (17)                          |          | 7 (11)      | 11 (17)                          |          |
| No UTI                                     | 388 (70)     | 51 (78)                          |          | 40 (81)     | 51 (78)                          |          |

*Propensity scores were calculated by logistic regression on two groups (carbapenem/cefuroxime) using a set of characteristics including recipient age, recipient sex, induction, transplant year, HLA, CIT, and PRA and grouped into 10 categories for 1:1 matching (carbapenem-to-cefuroxime).

SD, standard deviation; KT, kidney transplantation; HLA, human leukocyte antigen; CIT, cold ischemic time; PRA, panel-reactive antibody; ESKD, end-stage kidney disease; DN, diabetic nephropathy; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis; CGN, chronic glomerulonephritis; FSGS, focal segmental glomerulosclerosis; LN, lupus nephritis; HTN, hypertension; LRKT, living-related kidney transplantation; DDKT, deceased-donor kidney transplantation; IQR, interquartile range; UTI, urinary tract infection; ESC-R EB, extended-spectrum cephalosporin-resistant Enterobacteriaceae.
ESC-R EB Early UTI

After KT, early UTI occurred during the follow-up period in 182 (29%) patients in a whole cohort. Those included *E. coli* (*n* = 122), *K. pneumoniae* (*n* = 17), *Pseudomonas aeruginosa* (*n* = 9), *Enterobacter* spp. (*n* = 1), *Enterococcus* spp. (*n* = 19), *Staphylococcus* spp. (*n* = 11), *Streptococcus* spp. (*n* = 1), *Proteus mirabilis* (*n* = 5), *Candida* spp. (*n* = 12), and *Cryptococcus* spp. (*n* = 1). There were 167 (92%) and 15 (8%) patients developed monomicrobial and polymicrobial UTI, respectively. Of the latter, one patient had three isolated organisms. ESC-R EB accounted for 52% of the UTI cases. *E. coli* were susceptible to ertapenem (100%), meropenem (100%), amikacin (99%), piperacillin/tazobactam (92%), ceftazidime (67%), ceftriaxone (63%), cefotaxime (50%), cefotaxime (49%), amoxicillin/clavulanic acid (76%), trimethoprim/sulfamethoxazole (47%), levofloxacin (44%), and ciprofloxacin (43%). *K. pneumoniae* were susceptible to ertapenem (93%), meropenem (93%), amikacin (97%), piperacillin/tazobactam (79%), ceftazidime (75%), ceftriaxone (69%), cefotaxime (65%), amoxicillin/clavulanic acid (68%), trimethoprim/sulfamethoxazole (59%), levofloxacin (69%), and ciprofloxacin (65%).

Of those cases, 74 and 26% had asymptomatic bacteriuria and symptomatic UTI, respectively. Among those with urinary symptoms, 3% had cystitis, and 23% had acute allograft pyelonephritis (Figure 2A). ESC-R EB accounted for the majority (54%) of the UTI cases. Of these cases, 76% had asymptomatic bacteriuria and 24% had symptomatic UTI (cystitis 5%, pyelonephritis 19%) (Figure 2B).

In the cox proportional hazards model for factors associated with ESC-R EB UTI within 14 days after KT in the whole cohort (Table 2), cefuroxime use at peri-transplant period and female sex were associated with early ESC-R EB UTI in univariate analysis (hazard ratio [HR] 0.19; 95% confidence interval [CI], 0.05–0.75; *p* = 0.007). In multivariate analysis, carbapenems and female KT recipients remained independently associated with early ESC-R EB UTI (HR 0.19; 95%CI, 0.05–0.64; *p* < 0.001). After propensity score matching, the distributions of pathogens were *E. coli* (*n* = 24), *K. pneumoniae* (*n* = 4), *Pseudomonas aeruginosa* (*n* = 2), *Enterococcus* spp. (*n* = 6), *Staphylococcus* spp. (*n* = 2), *Proteus mirabilis* (*n* = 1), *Candida* spp. (*n* = 1), and *Cryptococcus* spp. (*n* = 1). There were 126 (97%) and 4 (3%) patients who were diagnosed with monomicrobial and polymicrobial UTI, respectively. ESC-R EB accounted for the majority (54%) of the UTI cases. Of these cases, 69% had asymptomatic bacteriuria and 31% had symptomatic UTI (cystitis 7%, pyelonephritis 24%) (Figure 2B). There were 3 (5%) KT recipients in the carbapenem group had ESC-R EB UTI, compared with 18 (28%) KT recipients with the cefuroxime group (*p* < 0.001) (Table 1). The cumulative incidences of ESC-R EB UTI estimated by the Kaplan–Meier method were 0.33% per day (5% per 14 days) in the carbapenem group and 2.20% per day (28% per 14 days) in the cefuroxime group (log-rank test = 0.003) (Figure 3).

In the Cox proportional hazards model, antibiotic prophylaxis was identified as a risk factor significantly associated with ESC-R EB UTI within 14 days after KT. In addition, carbapenems were found to be a protective factor against ESC-R EB UTI compared with cefuroxime (HR, 0.19; 95%CI, 0.05–0.64; *p* = 0.008) (Table 3).

Outcomes

In the whole cohort (*n* = 620), there were no differences between groups in composite outcomes (such as bacteremia, pyelonephritis, perinephric collection, nephrectomy, slow graft function, delayed graft function, and early allograft dysfunction). However, the duration of antibiotic use and length of hospital stay was significantly longer in the ESC-R EB UTI group.

In a propensity score-matched cohort, there were no differences in composite outcomes between KT recipients who did and did not develop ESC-R EB UTI (Table 4). However, KT recipients who developed ESC-R EB UTI had significantly increased median duration of antibiotic use (8 days; interquartile
### TABLE 2 | Cox proportional hazards model for factors associated with ESC-R EB UTI within 14 days after kidney transplantation in a whole cohort (n = 623).

| Factor                          | ESC-R EB UTI group (n = 97) | Non-ESC-R EB UTI group (n = 523) | Univariate analysis | Multivariate analysis |
|---------------------------------|----------------------------|---------------------------------|---------------------|-----------------------|
|                                | Hazard ratio (95% CI)       | p-value                         | Adjusted hazard ratio (95% CI) | p-value |
| Drug, n (%)                     |                            |                                 |                     |                       |
| Cefuroxime                      | 94 (17)                    | 461 (83)                        | Reference           | Reference             |
| Carbapenems                     | 3 (5)                      | 62 (95)                         | 0.19 (0.05–0.75)    | 0.019                 |
| Recipient age (year)            | 42 (12)                    | 43 (11)                         | 0.99 (0.97–1.01)    | 0.123                 |
| Recipient sex, n (%)            |                            |                                 |                     |                       |
| Male                            | 38 (10)                    | 355 (90)                        | Reference           | Reference             |
| Female                          | 59 (26)                    | 168 (74)                        | 3.11 (2.03–4.77)    | <0.001                |
| ESKD cause, n (%)               |                            |                                 |                     |                       |
| Unknown                         | 37 (17)                    | 179 (83)                        | Reference           |                       |
| Known                           | 60 (15)                    | 344 (85)                        | 0.96 (0.62–1.48)    | 0.857                 |
| Donor age (year), mean (SD)     | 40 (14)                    | 39 (14)                         | 1.00 (0.98–1.01)    | 0.919                 |
| Donor sex, n (%)                |                            |                                 |                     |                       |
| Male                            | 59 (15)                    | 332 (85)                        | Reference           |                       |
| Female                          | 38 (17)                    | 190 (83)                        | 1.12 (0.73–1.72)    | 0.596                 |
| History of donor fever, n (%)   |                            |                                 |                     |                       |
| No                              | 55 (17)                    | 267 (83)                        | Reference           |                       |
| Yes                             | 42 (14)                    | 255 (86)                        | 0.88 (0.58–1.34)    | 0.558                 |
| CIT (hours), median (IQR)       | 14.5 (0.5–19)              | 15 (0.6–8.5)                    | 1.00 (0.98–1.02)    | 0.943                 |
| Operation time (min), mean (SD) | 281 (68)                   | 281 (76)                        | 1.00 (0.92–1.09)    | 0.968                 |
| HLA mismatch, n (%)             |                            |                                 |                     |                       |
| 0, 1                            | 20 (13)                    | 130 (87)                        | Reference           |                       |
| 2, 3                            | 64 (16)                    | 337 (84)                        | 1.14 (0.68–1.91)    | 0.620                 |
| 4, 5, 6                         | 13 (19)                    | 56 (81)                         | 1.09 (0.72–2.03)    | 0.359                 |
| PRA, n (%)                      |                            |                                 |                     |                       |
| ≤50%                            | 89 (15)                    | 500 (85)                        | Reference           | Reference             |
| >50%                            | 8 (26)                     | 23 (74)                         | 1.71 (0.79–3.70)    | 0.173                 |
| Induction, n (%)                |                            |                                 |                     |                       |
| No                              | 15 (10)                    | 134 (90)                        | Reference           | Reference             |
| Yes                             | 82 (17)                    | 389 (83)                        | 1.60 (0.92–2.79)    | 0.096                 |

**ESC-R EB, extended-spectrum cephalosporin-resistant Enterobacterales; ESKD, end-stage kidney disease; UTI, urinary tract infection; CI, confidence interval; CIT, cold ischemic time; HLA, human leukocyte antigen; LRKT, living-related kidney transplantation; PRA, panel-reactive antibody; DDKT, deceased-donor kidney transplantation; IQR, interquartile range.**

We have reported a propensity score-matched cohort study involving adult KT recipients with similar baseline characteristics in a setting where an ESC-R UTI has been emerging among KT recipients. The results revealed that patients who received carbapenem perioperative prophylaxis had significantly decreased incidence of ESC-R EB UTI within 14 days after KT compared with patients who routinely received cefuroxime perioperative prophylaxis. The incidence of ESC-R EB infection increased the antibiotic duration and likely led to bloodstream infection after transplantation.

**DISCUSSION**

We have reported a propensity score-matched cohort study involving adult KT recipients with similar baseline characteristics in a setting where an ESC-R UTI has been emerging among KT recipients. The results revealed that patients who received carbapenem perioperative prophylaxis had significantly decreased incidence of ESC-R EB UTI within 14 days after KT compared with patients who routinely received cefuroxime perioperative prophylaxis. The incidence of ESC-R EB infection increased the antibiotic duration and likely led to bloodstream infection after transplantation.

UTI is a common complication after KT that was reported to occur in 34–42% of cases (18, 19), similar to the incidence of 30% in the present cohort. A recent retrospective study revealed a significantly high incidence of UTI after KT. Specifically, approximately half of the patients developed UTI within the first month postoperatively, with a median onset of 5 days. Although female sex was identified as an independent factor for UTI (within 1 month after KT) among KT recipients in a single transplant center (20), which is comparable to the results of an analysis in a whole cohort, therefore, we decided to match gender as one of the factors to omit the confounding effect and truly investigate the effect of antibiotic agents. Additionally, KT recipients are subjected to innate immunity impairment, mainly toll-like receptors (TLR). TLR2,
FIGURE 3 | Kaplan–Meier plots of ESC-R EB UTI within 14 days after KT in the cefuroxime and carbapenem groups within the propensity score-matched cohort (n = 130).

TABLE 3 | Cox proportional hazards model for factors associated with ESC-R EB UTI within 14 days after kidney transplantation in the propensity score-matched cohort (n = 130).

| Factors n (%) | ESC-R EB UTI group (n = 21) | Non-ESC-R EB UTI group (n = 109) | Univariate analysis |
|---------------|-----------------------------|----------------------------------|---------------------|
|               | Hazard ratio (95% CI)       | p-value                          |                     |
| Perioperative prophylaxis |                   |                                  |                     |
| Cefuroxime    | 18 (28)                     | 47 (72)                          | Reference           |
| Carbapenems   | 3 (5)                       | 62 (96)                          | 0.19 (0.05–0.64)    | 0.008               |
| History of donor fever |                   |                                  |                     |
| No            | 7 (25)                      | 21 (75)                          | Reference           |
| Yes           | 14 (14)                     | 88 (86)                          | 0.85 (0.31–2.36)    | 0.757               |
| Allograft type |                   |                                  |                     |
| LRKT          | 4 (40)                      | 6 (60)                           | Reference           |
| DDKT          | 17 (14)                     | 103 (86)                         | 1.32 (0.25–6.94)    | 0.742               |
| Operation time (min) (per 30 min) | 276 (58) | 288 (70)                         | 0.88 (0.69–1.13)    | 0.318               |

ESC-R EB, extended-spectrum cephalosporin-resistant Enterobacterales; UTI, urinary tract infection; CI, confidence interval; LRKT, living-related kidney transplantation; DDKT, deceased-donor kidney transplantation.

TLR4, and TLR5 are essential molecules in innate immunity to defend against pathogens in the genitourinary tract, and calcineurin inhibitors, especially tacrolimus, have been reported to decrease TLR5 expression in bladder macrophages while developing UTI (21, 22). Furthermore, most pathogens were Gram-negative bacilli which lately have been broader resistant to available antibiotics (20). Therefore, comprehensive prevention and treatment measures against known risk factors should be undertaken as early as possible to reduce UTI incidence. Due to a lacking of new effective antibiotics for multi-drug resistant Gram-negative pathogens, the properties of TLRs, as mentioned above, could provide an opportunity for ligand-drug alternatives (23).

A large meta-analysis of KT recipients found an overall rate of 10% for development of extended-spectrum beta-lactamase (ESBL)-producing EB UTI; however, this number could be as high as 33% among Asian KT recipients (24). A retrospective study from a single transplant center in China revealed rate of E. coli UTI in KT recipients of 12.5%, of that 73% were identified as having ESBL-producing pathogen and 64% carried adhesions-coding gene (25). In comparison, the incidence of ESC-R EB UTI in our cohort was relatively higher at 16%.
TABLE 4 | Outcomes of the kidney transplant recipients in the propensity score-matched cohort.

| Factors                      | ESC-R EB group (n = 21) | Non-ESC-R EB group (n = 109) | p-value |
|------------------------------|-------------------------|------------------------------|---------|
| Duration of antibiotic (days), median (IQR) | 8 (7–14)               | 0 (0–0)                     | <0.001  |
| Composite complications, n (%) | 8 (38)                  | 30 (28)                     | 0.329   |
| Bacteremia                   | 5 (24)                  | 1 (1)                       | <0.001  |
| Peri-allograft collection    | 1 (5)                   | 6 (5.5)                     | >0.999  |
| Recurrent UTI                | 0 (0)                   | 0 (0)                       | >0.999  |
| Nephrectomy                  | 0 (0)                   | 1 (1)                       | >0.999  |
| Delayed allograft function   | 4 (19)                  | 25 (23)                     | >0.999  |
| Total length of hospital stays (days), median (IQR) | 19 (15–21)             | 15 (11–23)                  | 0.123   |
| Hospital mortality, n (%)    | 0 (0)                   | 0 (0)                       | >0.999  |
| Allograft function; GFR (mL/min/1.73 m²), mean (SD) | 58.1 (23.5)             | 54.7 (20.0)                 | 0.488   |
| On day of discharge          | 60.0 (23.2)             | 57.7 (21.9)                 | 0.666   |
| At day 30                     | 57.5 (22.6)             | 57.7 (24.6)                 | 0.966   |

ESC-R EB, extended-spectrum cephalosporin-resistant Enterobacteriales; IQR, interquartile range; GFR, glomerular filtration rate; SD, standard deviation.

A previous retrospective propensity score-matched study revealed no significant impact of carbapenems compared with any other regimens within the first 72 h in preventing ESBL-producing EB bloodstream infection (26). Our recent study showed that carbapenems did not prevent ESC-R EB bloodstream infection (27). However, ESC-R EB was found to be the leading causative pathogen (50%) for bacteremia within the first year after KT, and 85% of the pathogens were considered to be derived from genitourinary sources (27).

ESC-R EB UTI was presented to be a cause of prolonged antibiotic duration both before and after matched analysis; these data emphasized a significant burden of antimicrobial stewardship, which could conserve patients’ microbiome and avoid dysbiosis. However, the hospital stay was longer in the whole cohort, which was not substantially different in the propensity score-matched cohort. Therefore, the length of hospitalization is subjected to multiple factors, including infections and other transplant-related issues. ESC-R EB UTI was found to be associated with high mortality rates in several previous studies (28–30), while our results indicated that it did not increase mortality. Additionally, we also did not observe an increasing rate of carbapenem-resistant Enterobacteriales, especially Metallo-ß-Lactamases, in our setting, which could threaten an emerging difficult-to-treat bacterial genitourinary tract infection in these vulnerable populations (31). Although no deaths were recorded during ESC-R EB-related UTI in our cohort, one patient developed allograft loss, and the rate of bacteremia was significantly higher in patients with ESC-R EB UTI, which could place patients at risk of unfavorable outcomes and morbidities.

The main strengths of the present study were the data from a large KT center with a high prevalence of ESC-R EB UTI and the presence of a preemptive urine analysis and culture monitoring protocol. This would have allowed us to retrieve the whole spectrum of UTI, including asymptomatic and symptomatic cases. However, our study had some limitations. The first was its retrospective design, which means that some of the collected patient data in the medical records may have been missing. The second was that the data did not enable us to postulate an effective method against ESBL-producing EB because phenotypic tests were not conducted to confirm ESBL enzyme production. The third was that although a relatively large number of participants were enrolled, the number of participants after matching was limited, which could have prevented us from exploring other risk factors. However, we corrected the unbalanced background characteristics between the two groups to accurately evaluate the effectiveness of carbapenems in preventing ESC-R EB UTI. Finally, the follow-up time was relatively short. Therefore, a prospective study design with a larger number of matched patients together with a more extended follow-up period would yield more statistically significant differences.

Furthermore, the American Society of Transplantation Infectious Diseases Community of Practice recommended using single first-generation cephalosporins such as cefazolin for perioperative prophylaxis in KT recipients (32). Instead, our data propose the potential use of antibiotic prophylaxis based on local epidemiology, predominant with ESC-R EB early UTI, which could lead to post-surgical complications.

In conclusion, ESC-R EB UTI is a potentially serious condition that can arise after KT. Consequently, prevention of this infection should be considered. In a well-balanced retrospective analysis, the present study showed that administration of carbapenem peri-transplant prophylaxis can significantly protect against ESC-R EB UTI early after KT. Appropriate antibiotics coverage during the peri-transplant period could potentially omit infection among KT recipients. Further prospective studies should focus on this particular infection prevention strategy. Furthermore, non-pharmacological interventions such as early urinary prosthesis removal should be encouraged to avoid complicated UTIs from the uropathogenic pathogen.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Faculty of Medicine Ramathibodi
Hospital, Mahidol University (MURA 2019/806). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

JB conceptualized and designed the study. SA, NA, PC, and JB collected the data. SA and JB analyzed data and draft manuscript. All authors reviewed and approved a final version of the manuscript.

REFERENCES

1. Noppakun K, Ingathit A, Pongskul C, et al. A 25-year experience of kidney transplantation in Thailand: report from the Thai Transplant Registry. Nephrology (Carlton). (2015) 20:177–83. doi: 10.1111/nep.12378
2. Adamska Z, Karczewski M, Cichanska L, et al. Bacterial infections in renal transplant recipients. Transplant Proc. (2015) 47:1808–12. doi: 10.1016/j.transproceed.2015.03.046
3. Memikoglu KO, Keven K, Sengul S, Soyapacci Z, Erturk S, Erbay B. Urinary tract infections following renal transplantation: a single-center experience. Transplant Proc. (2007) 39:3131–4. doi: 10.1016/j.transproceed.2007.10.005
4. Ak O, Yildirim M, Kucuk HF, Gencer S, Demir T. Infections in renal transplant patients: risk factors and infectious agents. Transplant Proc. (2013) 45:944–8. doi: 10.1016/j.transproceed.2013.02.080
5. Kiro E, Asrat D, Ayenew Z, Tsige E. Bacterial urinary tract infection among adult renal transplant recipients at St. Paul’s hospital millennium medical college, Addis Ababa, Ethiopia BMC Nephrol. (2019) 20:289. doi: 10.1186/s12882-019-1485-9
6. Saemann M, Horl WH. Urinary tract infection in renal transplant recipients. Eur J Clin Invest. (2008) 38:58–65. doi: 10.1111/j.1365-2362.2008.02014.x
7. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. (1998) 338:1741–51. doi: 10.1056/NEJM199806133384207
8. Brakemeier S, Taxeidi SI, Zukunft B, et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae-related urinary tract infection in kidney transplant recipients: risk factors, treatment, and long-term outcome. Transplant Proc. (2017) 49:1757–65. doi: 10.1016/j.transproceed.2017.06.033
9. Behzadi P, Urbán E, Matuz M, Benko R, Gajdács M. The Role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. Adv Exp Med Biol. (2021) 1323:35–69. doi: 10.1007/5584_2020_566
10. Behzadi P, García-Perdomo H, Karpiński TM. Toll-like receptors: general molecular and structural biology. J Immunol Res. (2021) doi: 10.1155/2021/7082062
11. Issakhanian L, Behzadi P. Antimicrobial agents and urinary tract infections. Curr Pharm Des. (2019) 25:1409–23. doi: 10.2174/1381612825999190619130216
12. Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. (2019) 33:e13507. doi: 10.1111/ctr.13507
13. Performance standards for antimicrobial susceptibility testing M100-S20. CLSI. 2010.
14. Pourmand G, Salem S, Mehrsai A, Taherimahmoudi M, Ebrehimi R, Pourmand MR. Infectious complications after kidney transplantation: a single-center experience. Transpl Infect Dis. (2007) 9:302–9. doi: 10.1111/j.1399-3062.2007.00229.x
15. Behzadi E, Behzadi P. The role of toll-like receptors (TLRs) in urinary tract infections (UTIs). Gent European J Urol. (2016) 69:404–10. doi: 10.5173/eu.2016.871
16. Emal D, Rampanelli E, Claassen N, Bemelman FJ, Leemans JC, Florquin S, et al. Calcineurin inhibitor Tacrolimus impairs host immune response against urinary tract infection. Sci Rep. (2019) 9:106. doi: 10.1038/s41598-019-37482-x
17. Siritip N, Nongnuch A, Dajsakdipon T, Thongprayoon C, Cheungprasitporn W, Bruminhent J. Epidemiology, risk factors, and outcome of bloodstream infection within the first year after kidney transplantation. Am J Med Sci. (2020) 306:1352–7. doi: 10.1016/j.amjms.2020.10.011
18. Pourmand G, Salem S, Mehrsai A, Taherimahmoudi M, Ebrehimi R, Pourmand MR. Infectious complications after kidney transplantation: a single-center experience. Transpl Infect Dis. (2007) 9:302–9. doi: 10.1111/j.1399-3062.2007.00229.x
19. Rosado-Canto R, Parra-Avila I, Tejeda-Maldonado J, et al. Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial. Nephrol Dial Transplant. (2020) 35:1996–2003. doi: 10.1093/ndt/gzaa251
20. Ma ZZ, Li L, Han XX, Duan YD, Wang WZ, Niu ME. Analysis of risk factors for early urinary tract infection after kidney transplantation. Trans Androl Urol. (2020) 9:2211–7. doi: 10.21037/tau-20-1248
21. Behzadi E, Behzadi P. The role of toll-like receptors (TLRs) in urinary tract infections (UTIs). Gent European J Urol. (2016) 69:404–10. doi: 10.5173/eu.2016.871
22. Emal D, Rampanelli E, Claassen N, Bemelman FJ, Leemans JC, Florquin S, et al. Calcineurin inhibitor Tacrolimus impairs host immune response against urinary tract infection. Sci Rep. (2019) 9:106. doi: 10.1038/s41598-019-37482-x
23. Behzadi P, García-Perdomo HA, Karpinski TM. Toll-like receptors: general molecular and structural biology. J Immunol Res. (2021) doi: 10.1155/2021/9914854
24. Alevizakos M, Nasiosoudis G, Mylonakis E. Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. (2017) 19:2759. doi: 10.1111/tid.12759
25. Wang Q, Zhao K, Guo C, Li H, Huang T, Ji J, et al. Antibiotic resistance and virulence genes of Escherichia coli isolated from patients with urinary tract infections after kidney transplantation from deceased donors. Infect Drug Resist. (2021) 14:4039–46. doi: 10.2147/IDR.S332897
26. Pierrotti LC, Pérez-Nadela E, Fernández-Ruiz M, et al. Efficacy of β-lactam/β-lactamate inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacteriales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project). Transpl Infect Dis. (2020) 23:e13520.
27. Siripit N, Nongnuch A, Dajasakdipon T, Thongprayoon C, Cheungprasitporn W, Bruminhent J. Epidemiology, risk factors, and outcome of bloodstream infection within the first year after kidney transplantation. Am J Med Sci. (2021) 361:352–7. doi: 10.1016/j.amjms.2020.10.011
28. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum beta-lactamase-producing

ACKNOWLEDGMENTS

We are grateful to the Ramathibodi Excellence Center for Organ Transplantation, Faculty of Medicine Ramathibodi Hospital, Mahidol University for providing the patient data.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.841293/full#supplementary-material
Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. *Antimicrob Agents Chemother.* (2007) 51:1987–94. doi: 10.1128/AAC.01000-07

29. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Cisneros JM, Peña C, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *J Clin Microbiol.* (2010) 48:1726–31. doi: 10.1128/JCM.02353-09

30. Freeman JT, McBride SJ, Nisbet MS, et al. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes. *Int J Infect Dis.* (2012) 16:e371–4. doi: 10.1016/j.ijid.2012.01.008

31. Behzadi P, García-Perdomo HA, Karpinski TM, Issakhanian L. Metallo-ß-lactamases: a review. *Mol Biol Rep.* (2020) 47:6281–94. doi: 10.1007/s11033-020-05651-9

32. Abbo LM, Grossi PA, AST ID. Community of Practice. Surgical site infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice *Clin Transplant.* (2019) 33:e13589. doi: 10.1111/ctr.13589

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.